Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer
But Has Ground To Make Up On Tecentriq
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
You may also be interested in...
Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.
Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.